Skip to main content

Drug Interactions between Cerianna and toremifene

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

toremifene fluoroestradiol F 18

Applies to: toremifene and Cerianna (fluoroestradiol F 18)

GENERALLY AVOID: Coadministration of the radioactive diagnostic agent fluoroestradiol F 18 with drugs that block the estrogen receptor (ER), such as tamoxifen and fulvestrant, may reduce the uptake of fluoroestradiol F 18 into ER-positive tumors. This may therefore reduce its potential to detect ER-positive non-primary breast cancer lesions. Fluoroestradiol F 18 binds to the ER and its uptake in human tumors is dependent on ER density and function in tumors and physiologic issue, including in the liver, ovaries, and uterus. The effect of selective ER modulators such as tamoxifen and ER down-regulators such as fulvestrant may persist for up to 8 and 28 weeks, respectively. In clinical studies, treatment with ER modulators or fulvestrant was discontinued 60 days prior to the administration of fluoroestradiol F 18. However, concurrent use of aromatase inhibitors was permitted in these clinical studies.

MANAGEMENT: Concomitant use of fluoroestradiol F 18 with systemic endocrine therapy that targets estrogen receptors, including estrogen receptor modulators such as tamoxifen and estrogen receptor down-regulators such as fulvestrant is not recommended. Administration of fluoroestradiol F 18 is recommended prior to starting treatment with these drugs. However, the manufacturer advises that treatment with estrogen receptor modulators or down-regulators should not be delayed in order to administer fluoroestradiol F 18.

References (1)
  1. (2022) "Product Information. Cerianna (fluoroestradiol F 18)." GE Healthcare

Drug and food interactions

Moderate

toremifene food

Applies to: toremifene

GENERALLY AVOID: Coadministration with grapefruit juice may theoretically increase the plasma concentrations of toremifene. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism by certain compounds present in grapefruit. Because toremifene is associated with dose- and concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.

GENERALLY AVOID: Due to their estrogenic effect, isoflavones present in soy such as genistein and daidzein may stimulate breast tumor growth and antagonize the antiproliferative action of toremifene. Supportive data are derived primarily from in vitro and animal studies. In vitro, low concentrations of these phytoestrogens have been found to promote DNA synthesis and reverse the inhibitory effect of tamoxifen on oestrogen-dependent breast cancer cell proliferation. In contrast, high concentrations of genistein greater than 10 microM/L have been found to enhance tamoxifen effects by inhibiting breast cancer cell growth. It is not known if these high concentrations are normally achieved in humans. Plasma concentrations below 4 microM/L have been observed in healthy volunteers given a soy diet for one month or large single doses of genistein. These concentrations are comparable to the low plasma concentrations associated with tumor stimulation reported in animals. In a study of 155 female breast cancer survivors with substantially bothersome hot flashes, a product containing 50 mg of soy isoflavones (40% to 45% genistein; 40% to 45% daidzein; 10% to 20% glycitein) taken three times a day was found to be no more effective than placebo in reducing hot flashes. No toxicity or recurrence of breast cancer was reported during the 9-week study period.

MANAGEMENT: Until more information is available, patients treated with toremifene should consider avoiding the consumption of grapefruit juice and soy-containing products. Patients should be advised to contact their physician if they experience vaginal bleeding or potential signs of blood clots such as chest pain, shortness of breath, sudden loss of vision, and pain, redness or swelling in an extremity. Patients should seek immediate medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.

References (2)
  1. (2001) "Product Information. Fareston (toremifene)." Schering Corporation
  2. Therapeutic Research Faculty (2008) Natural Medicines Comprehensive Database. http://www.naturaldatabase.com

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.